Zhitong Finance App News, Maike Pharmaceutical-B (02335.HK) announced that the phase II clinical trial of MT200605, a drug candidate developed independently by the Group to treat acute ischemic stroke, has been completed. The clinical trial has proven to have significant and robust efficacy advantages and good safety.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.